Navigation Links
China Sky One Medical Raises $25 Million in Private Placement
Date:2/1/2008

HARBIN, China, Feb. 1 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it raised $25 million in a private placement of 2.5 million shares of the Company's common stock, with 30% warrant coverage. The warrants have an exercise price of $12.50 per share and a term of 3 years.

China Sky One Medical intends to use the proceeds from the offering for acquisitions, working capital and sales and marketing for new products.

Global Hunter Securities acted as the sole placement agent in this transaction.

This transaction will be described in more detail in the Form 8-K and other supporting documents China Sky One Medical will file with the Securities and Exchange Commission.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR'') and Harbin First Bio- Engineering Company Limited ("First"), the Company's principal revenue source is the manufacture and sale of over-the- counter pharmaceutical products. http://www.skyonemedical.com

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically
'/>"/>

SOURCE China Sky One Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. DuPont Opens Fluoropolymer Production Plant in China
2. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
3. China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008
4. China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Womens Health Issues
5. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
6. Knee Implant Market Booming in China
7. Chinas biotech industry: An Asian dragon is growing
8. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
9. China Sky One Medical Appoints Independent Auditor
10. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
11. MM2 Group Establishes New Venture for Sofgel Manufacture in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... Leukemia and myeloproliferative disorders are serious and often ... 51st Annual Meeting of the American Society of ... diagnostic methods for patients suffering from acute promyelocytic ... and myelofibrosis that are based on a better ...
(Date:12/5/2009)... Solutions, an innovative new international private medical insurance plan which follows ... offering customers the flexibility to add or remove a wide range ... customers to tailor their benefits to complement those already offered in ... ...
(Date:12/4/2009)... Inc. (NYSE: CRE ) ("Care" or the "Company") ... of $0.17 per share of common stock. The dividend is ... December 14, 2009. ,, About Care Investment ... investment and finance company investing in healthcare-related real estate and commercial ...
(Date:12/4/2009)... Association of Homes and Services for the Aging (AAHSA) applauds ... Supportive Services (CLASS) provisions remain in the final health reform ... to elders, people with disabilities and their caregivers. ,, ... bill that will make it affordable to care for families ...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chief Information Officer ... the "Chief Innovation Officer" Appy Award for transforming Crescent,s ... recipients are nominated based on their innovative usage of ... levels of customer success to their sales, marketing, partner, ...
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
... as cholera would take the heaviest toll on survivors ... camps has intensified// the spread of pneumonia, and health ... in the already devastated region. ,In the ... groups such as the World Health Organization issued statements ...
... A recent study shows , schizophrenics treated with ... risk for developing type 2 diabetes. Patients taking ... impairment of glucose effectiveness compared with patients taking ... non-obese people with schizophrenia or schizoaffective disorder who ...
... world is infected with tuberculosis every second and someone dies ... have discovered easier tests to detect this deadly disease in ... generally done with a gastric lavage. It's an invasive test ... a sputum sample. Sputum is what comes up when you ...
... for urinary tract infections also put them at risk for ... ,Researchers interviewed 242 women who were treated for kidney ... automated databases. They then compared data from these cases to ... history of kidney infections. ,Results of the study showed ...
... after a mastectomy does not reduce the long-term survival of ... had a better chance of survival than those who did ... may boost the morale and self-esteem of the patient, which ... implants could stimulate the immune system and reduce blood flow ...
... can help maintain cognitive skills in people as they ... For the study researchers reviewed data on 295 men ... and Netherlands Elderly (FINE) study. The length and intensity ... cognitive function was evaluated starting in 1990. ,Results ...
Other Medicine News:
(Date:12/4/2009)... 4 Hospira, Inc. (NYSE: HSP ), ... today announced the launch of its next-generation 50 mL ... and solutions, and now offers a complete size range ... responsible VisIV product. The launch of the 50 mL ...
(Date:12/4/2009)... developers of the AcceleDent System , which ... the availability of a new Continuing Education course ... in professional education for many industries, including medicine ... views about orthodontic treatment, a summary of treatment ...
(Date:12/4/2009)... 4 AstraZeneca (NYSE: AZN ) today ... has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release ... with Major Depressive Disorder (MDD). SEROQUEL XR is the ... to treat both major depressive disorder as adjunctive therapy ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Football Pros in October Pink Gloves 58529 1Football Pros in October Pink Gloves 58529 2Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 1Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 2Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 3Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 1Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 2Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 3
... EMERYVILLE, Calif., Dec. 5 Neurobiological,Technologies, Inc. (Nasdaq: ... Holdings L.P. ("Celtic Pharma") presented interim results,for XERECEPT(R) ... Neuro-Oncology., Paul Freiman, President and Chief Executive ... continuing involvement in the development of XERECEPT,and the ...
... NEW YORK, Dec. 4 The Michael J. ... in total funding for five clinical research studies ... the Foundation,s focus on,accelerating scientific solutions that can ... initiative funds clinical research projects,with strong potential to ...
Other Medicine Technology:Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 2Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 3Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 4Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program 2Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program 3
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
... bronchofiberscope yet. The BF-3C40's distal end measures ... the previous model. It also offers better ... to the use of extra-fine optical fibers ... size by 70 percent. Images are clearer, ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
Medicine Products: